Differential Cell Surface Protein Expression In Response To Parp Inhibition In Brca1 Mutant Isogenic Ovarian And Breast Cancer Cells Using A Novel Proteomic Technique

Objective: Poly(ADP-ribose) polymerase inhibitors (PARPi) have shown tremendous promise as chemotherapeutic agents targeting tumors with defective homologous recombination repair. Recent data suggest that PARPi may modulate immune response independent of BRCA status. However, little is understood about cellular changes induced by PARPi. We sought to evaluate changes in gene expression by BRCA1 mutant and wildtype (WT) ovarian and breast cancer cells following PARPi therapy.